Neonatal group B streptococcus disease in developing countries: are we ready to deploy a vaccine?
| Autor: | Pui Ying Iroh Tam, Stephen K. Obaro, Shirley F. Delair |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Immunology Population Disease medicine.disease_cause Infant Newborn Diseases Streptococcus agalactiae Sepsis Streptococcal Infections Drug Discovery Case fatality rate medicine Prevalence Humans Intensive care medicine education Developing Countries reproductive and urinary physiology Disease burden Pharmacology education.field_of_study Neonatal sepsis business.industry Public health Streptococcal Vaccines Infant Newborn Infant bacterial infections and mycoses medicine.disease Vaccination bacteria Molecular Medicine business |
| Zdroj: | Expert review of vaccines. 14(11) |
| ISSN: | 1744-8395 |
| Popis: | Group B streptococcus (GBS) disease is the leading cause of neonatal sepsis in developed countries and has high case fatality rates. In developing countries, however, the burden of GBS is less clear; this is due to a lack of studies using optimal diagnostic, clinical and laboratory techniques and is complicated by the wide availability of non-prescription antibiotics to the general population and in peripartum patients. There is an urgent need for prospective, population-based surveillance to provide an accurate assessment of neonatal GBS disease burden in developing countries, which remains largely unrecognized, and consequently obscures the potential relevance of GBS vaccination in these populations. Preliminary data on GBS vaccines are promising as a preventive tool for neonatal GBS infection, more so than any other currently available public health initiative. However, how do we assess the true impact of a GBS vaccine without accurate surveillance data on the real burden of disease? |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|